國家衛生研究院 NHRI:Item 3990099045/10403
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 913443      在线人数 : 1153
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10403


    题名: Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
    作者: Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A
    贡献者: National Institute of Cancer Research
    摘要: Background: Liposomal irinotecan (nal-IRI) plus 5-FU/LV is approved in the US for patients (pts) with mPAC previously treated with gemcitabine-based therapy. Primary analysis from NAPOLI-1 (NCT01494506) showed a significant median survival advantage for nal-IRI + 5-FU/LV vs 5-FU/LV (6.1 vs 4.2 mo; HR 0.67; 95% CI 0.49-0.92; P = 0.012; Wang-Gillam et al, Lancet. 2016). The most common TEAEs included diarrhea, vomiting, nausea, decreased appetite, fatigue, neutropenia, and anemia. Here we report incidence and prevalence of selected TEAEs over time in NAPOLI-1. Methods: Pts were randomly assigned to nal-IRI + 5-FU/LV, nal-IRI, or 5-FU/LV. In this post hoc analysis (data cutoff, Feb 14, 2014), incidence (ie, first occurrence) and prevalence (ie, first occurrence, ongoing event, or recurrence) of selected TEAEs were analyzed by treatment period (first 6 wk [period 1], second 6 wk [period 2], and beyond second 6 wk [period 3]). Denominators for percentages were the number of pts in the risk set during each period (for incidence: pts still on treatment without a previous event; for prevalence: all safety-evaluable pts). Results: 398 pts were treated with nal-IRI + 5-FU/LV (n = 117), nal-IRI (n = 147), or 5-FU/LV (n = 134). In the nal-IRI + 5-FU/LV arm, most first occurrences of neutropenia, diarrhea, nausea, and vomiting were during the first 6 wk of treatment, with incidence and severity generally decreasing thereafter (Table). Similarly, prevalence and severity were highest in the first 6 wk and tended to decrease over time. Similar trends were observed in the nal-IRI and 5-FU/LV arms. Conclusions: Neutropenia, diarrhea, nausea, and vomiting typically first occur early during the course of treatment with nal-IRI + 5-FU/LV and tend to decrease in incidence and severity thereafter.
    日期: 2016-10
    關聯: Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P.
    Link to: http://dx.doi.org/10.1093/annonc/mdw371.85
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000393912500699
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85018032900
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000393912500699.pdf103KbAdobe PDF217检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈